## **SUPPLEMENTARY FIGURES**

GO.MF		stats		9		2 8 3	2	0			0	N N				N	N			~	77	1	dib.
	17400044	1.000	Include on here	1000	NU-RUNC	ANH I	FINE	NON	IN D	110	DKN	CIO O	RM	00	ACC	MYA	N N	STR	MS	N54	A2G	SU	SILI
Term name	Term ID	p-vane	o -togroup-vaner	16 27 2	8 5 5	9.9	2 2 0	23	2 8 5	33	1 2 2	2 8 5	8 8	121	5 4 5	2 3	C 8	12 1		18	8 0	63	2 3
molecular_function	GD:0003674	4.198×10°12	and the second se					H															
sealing to do a	G0.0005480	1.496410						++			++		-						++		-		
on birding	60.0043167	5.033+10-5	_	-													-						
dentical protein binding	GO-0042802	5.342×10 <sup>-3</sup>															•7		ГD.	•			
cyclin-dependent protein serine/threonine kinase inhibitor	GO:0004861	6.982×10 <sup>-3</sup>																11					
DNA binding	GD:0003677	8.166×10 <sup>-3</sup>																					
single-stranded DNA binding	GD:0003697	1.601×10 <sup>-2</sup>																					
catalytic activity	GO:0003824	1.887×10-2																					
anion binding	GD:0043168	2.332×10°=						-															
netwocyclic compound binding organic cyclic compound binding	GO:0097159	4.485×10 <sup>-2</sup>																					
						-		-												2			
SC BP		stats		80	7 - 2	NIS MIL	RA	8.			0 1	MM	2 2 5	0	1 .	. 2	4			a	FAA	17	D
lerm name	Term ID	p-value	-log10(p-value)	0157	MC21	AHO1	NCC3	ON2A	INIP INIP	IFMI	CNIN	NV2	MD	XCR4	1004	= 0.51	NBLI	TRIP2	ASH	15430	1538	SUN5	ILIP2
sinionical process	60.0008150	2,439+10-10	0					1															
ellular process	GO:0009987	5.716×10-9	and the second se													H							
netabolic process	GO:0008152	1.401×10 <sup>-6</sup>															_						
organic substance metabolic process	GO:0071704	3.365×10 <sup>-6</sup>																					
ellular biosynthetic process	GO:0044249	4.388×10 <sup>-6</sup>																					
iosynthetic process	GO:0009058	7.428×10 <sup>-6</sup>		_											$\square$		_						
ellular metabolic process	GO:0044237	1.033×10 <sup>-5</sup>	_					-		- 22					44				-	- 2			-
rimary metabolic process	GD:0044238	4,040×10 <sup>-5</sup>								-	+				++					- 2			-
itropen compound metabolic process	GD:00(9807	6.902 x 10-5						F.															
evelopmental process	60.00325622	1.202 + 10-4						F.															
ucleic acid metabolic process	GD:0090304	1.350+10-4						Ē.					1										
natomical structure development	GO:0048856	2.271 = 10-4																					
egulation of biological process	GD:0050789	4.145×10 <sup>-4</sup>																					
sulticellular organism development	GO:0007275	4.412×10 <sup>-4</sup>																					
ucleobase-containing compound metabolic process	60:0006139	5.199×10 <sup>-4</sup>	-																				
ystem development	GO:0048731	6.752×10 <sup>-4</sup>	-																				
ell morphogenesis	GD:0000902	7.370×10-4	-			-		4												1			
ellular macromolecule metabolic process	60:0044260	7.743×10 <sup>-4</sup>						۳.															
eserocycle metabolic process	GC10046483	7.867×10**		-										1						-			
esponse to sterillus andation of califier represe	60,0050796	8.078×10-4											1										
eguation or central process ellular accentric comprised metabolic ecores	60.0006725	8725+10-4	-							10	+-						-		-				-
iological regulation	GO:0065007	1.127×10-3	-							171													
ellular response to stimulus	GO:0051716	1.263×10 <sup>-3</sup>																					
rganic cyclic compound metabolic process	GO:1901360	1.469×10 <sup>-3</sup>																					
nacromolecule metabolic process	GO:0043170	1.645×10 <sup>-3</sup>	-																				
sulticellular organismal process.	GO:0032501	1.656×10 <sup>-3</sup>	-																				
ellular nitrogen compound metabolic process	GO:0034641	2.924×10 <sup>-3</sup>																					
ellular macromolecule biosynthetic process	GD:0034645	3.417×10 <sup>-3</sup>															_						
egulation of mecromolecule metabolic process	60:0060255	4.255×10 <sup>-5</sup>	-			-																	
NA-dependent DNA replication maintenance of fidelity	GO:0045005	4.294×10 <sup>-3</sup>	-					-			-								-				
nex metabolic process	000000239	6.135-10-3	-					-		100							-						
automotical analytical process	60-0051171	6 157, 10-3	-			-											- 2			- 2			
equilation of primary metabolic process	60.0040090	8.925×10'3	<b>a</b>																				
mmune system process	GO-0002176	8.978×10 <sup>-3</sup>																					
egulation of metabolic process	GO-0019222	1.149×10 <sup>-2</sup>																					
egulation of cellular metabolic process	GO:0031323	1.334×10 <sup>-2</sup>																					
egulation of nucleobase-containing compound metabolic	GO:0019219	1.452×10 <sup>-2</sup>																					
egulation of immune system process	GO:0002682	1.577×10 <sup>-2</sup>									100												
ucleobase-containing compound biosynthetic process	50:0034654	1.852×10 <sup>-2</sup>																					
ellular nitrogen compound biosynthetic process	GO:0044271	1.972×10'2		-				-															
natomical structure morphogenesis	GD:0009653	2.027×10'2				-		-															
egative regulation of immune system process	60.0002685	2.148×10*									100			100									
atamouda hisoarthatic neorary	60-0019130	2.164.10-2						-						<b>C</b> (		-				10			
constic commund biosenthetic response	60:0019438	2.211+10-2														- 2	- 2						
ell differentiation	GO:0030154	2.852×10-2						-						10		n				0			
rganic cyclic compound biosynthetic process	GO:1901362	3.154×10 <sup>-2</sup>												<b>C I</b>		1	_			70			
ellular developmental process	GO:0048869	3.406×10 <sup>-2</sup>																					
rganonitrogen compound metabolic process	GO:1901564	3.464×10 <sup>-2</sup>																					
cellular response to DNA damage	GD:0006974	3.735×10 <sup>-2</sup>				-			-		-								-				
occ		stats		9		2 K Z	3	8		2	0	No. 1				N	~			N	2 2	1	10
ante exercis	Term ID	n-analas	deelitinaatus	E-010	NURD NUC	MHE	FIMO	NON5	IN D	TITIM	DKNI	GUA	RMD	Dice	T NO	MYM	NEM.	TRIP	MSH	NF43	1262	STV SAVA	NOL
IT TALE I MARCINE	APIN ID	p-value	0 regroup-value)	16 17	9 2 0	1212	2 2 0	23	19 2	133	2 2	10 6	H S	4	n X S	2 8	5 8	2	101	0 10	8.0	63	> 8
ellular anatomical entity	GO:0110165	9.008×10 <sup>-11</sup>																					
ellular_component	GO:0005575	1.219×10 <sup>-10</sup>																					
traceTular	GD:0005622	6.515×10 <sup>-9</sup>						H															
rganete toccali doc constanile	60.0043226	9.886×10 °						P										-					
sentrane lourded organile	60.0043229	4.001+10-6	-				- <b>1</b>	H				-											
Asolesm	60.0005737	2.369+10-5																					
tracellular membrane-bounded organelle	GD:0043231	5.038+10-5	-					Ē.														1	
ucleus	60:0005634	3.859 + 10-4																				1	
embrane-enclosed lumen	GO:0031974	1.179×10 <sup>-2</sup>																					
tracellular organelle lumen	GO:0070013	1.179×10 <sup>-2</sup>																					
garelle lumen	GO:0043233	1.179×10 <sup>-2</sup>																					
uclear lumen	GO:0031981	3.306×10 <sup>-2</sup>																					
icleoplasm embrane	G0:0005654 G0:0036030	3.522×10 <sup>-2</sup>									8	8			2								
		A MARK ST	-	-		-	-						-	-					-				
												1.00											
166		stats		Caop	NL	SAM	RAN D	000		MIT	CDK	MAGE	100	8	H	ZM	NZN	5	z .	ZNE	FAMI	STA	DM
פרות הגוווים	Term ID	p-value	o -log10(p-value)	15H	Rb8	HDI	102	N2A	All NID	TIMI	NIN NIA	A10	808	CR4	104	5WIA	1811	up2	SH3	430	020	LAS N	GLA
GG root term	KEGG:00000	7.120×10 <sup>-6</sup>		111											100								
ancreatic cancer	KEGG:05212	1.061×10 <sup>-5</sup>							1								1						
athways in cancer	KEGG 05200	7.091 × 10 <sup>-5</sup>	-																				
adder cancer	KEGG:05219	1.431×10 <sup>-4</sup>																					
uman cytomegalovirus infection	KEGG 05163	7.723×10-4																	-				
latinum drug resistance	KEGG:01524	7.893 + 10-4																					
IcroRNAs in cancer	KEGG-05206	8.665×10"*	-					٠.															
ocal admesioni intervoluzione la concrae	KEGG(04510	1.637×10 **																					+++
nournall call long carrier	KEGG 05223	4706×10-2						1		11													
and the second se	10,000 A 10,00		-					-		1.1													

**Supplementary Figure 1. The enrichment analysis of 42 up-regulated genes in metastatic melanoma.** In this chart, the GO (MF, BP and CC) and KEGG items that are significantly enriched were listed from the top to bottom. The information contained is mainly: term name, term ID, adjusted p-value, negative log10 of adjusted p-value and correlated genes. In the negative log10 of adjusted p-value column, the color (blue>green>yellow) and length of the bar represented the size of the p-value, as well as significance. In the rear grid, colored squares indicated that the single gene was involved in this GO function or pathway. The different color represents different verification methods: red squares represent inferred from experiment [IDA, IPI, IMP, IGI, IEP], direct assay [IDA], mutant phenotype [IMP], genetic interaction [IGI] and physical interaction [IPI]; blue squares represent inferred from high throughput experiment; green squares represent Traceable author [TAS], Non-traceable author [NAS], Inferred by curator [IC]; yellow squares represent expression pattern [IEP], sequence or structural similarity [ISS], genomic context [IGC], sequence model [ISM], sequence alignment [ISA], sequence orthology [ISO], biological aspect of ancestor [IBA] and rapid divergence [IRD]; azure squares represent reviewed computational analysis [RCA], electronic annotation [IEA]. In addition, the blank squares indicated that the gene is not correlated to the enriched function or pathway.



**Supplementary Figure 2. The enrichment analysis of 97 down-regulated genes in metastatic melanoma.** In this chart, the GO (MF, BP and CC) and KEGG items that are significantly enriched were listed from the top to bottom. The information contained is mainly: term name, term ID, adjusted p-value, negative log10 of adjusted p-value and correlated genes. In the negative log10 of adjusted p-value column, the color (blue>green>yellow) and length of the bar represented the size of the p-value, as well as significance. In the rear grid, colored squares indicated that the single gene was involved in this GO function or pathway. The different color represents different verification methods: red squares represent inferred from experiment [IDA, IPI, IMP, IGI, IEP], direct assay [IDA], mutant phenotype [IMP], genetic interaction [IGI] and physical interaction [IPI]; blue squares represent inferred from high throughput experiment; green squares represent Traceable author [TAS], Non-traceable author [NAS], Inferred by curator [IC]; yellow squares represent expression pattern [IEP], sequence or structural similarity [ISS], genomic context [IGC], sequence model [ISM], sequence alignment [ISA], sequence orthology [ISO], biological aspect of ancestor [IBA] and rapid divergence [IRD]; azure squares represent reviewed computational analysis [RCA], electronic annotation [IEA]. In addition, the blank squares indicated that the gene is not correlated to the enriched function or pathway.



**Supplementary Figure 3. The clinical correlation of CDKN1A, CDKN2A, CXCR4 and RAD51.** (A) The molecular distortion panorama of 4 key genes in 472 melanoma samples with clinical data from TCGA. From top to bottom panels indicate: mutation spectrum, sex, diagnosis age, American Joint Committee on Cancer metastasis stage code, overall survival, disease free, American Joint Committee on Cancer tumor stage code, the heatmap of gene alteration, expression level and methylation of CDKN1A, CDKN2A, CXCR4 and RAD51, GADD45B. The key to the color-coding is at the bottom. (B) The ROC curves of 4 key genes in melanoma patients. (C) The survival curves of 4 key genes between 2 groups with high or low expression levels, red lines represent high expression level, blue lines represent low expression level. The logrank p-value, HR (high) and p-value (HR) were listed.



**Supplementary Figure 4. The prognostic analysis of GADD45B molecular network (13-gene signature).** (A) LASSO coefficients profiles of genes in GADD45B network. (B) LASSO regression with tenfold cross-validation obtained 13 prognostic genes using minimum lambda value. (C) From top to bottom: The curve of risk score; the survival status of the patients. More dead patients corresponding to the higher risk score; the heatmap of the expression profiles of the 13 prognostic genes in low- and high-risk group. (D) Kaplan–Meier survival analysis of the 13-gene signature. (E) Time-dependent ROC analysis of the 13-gene signature. ROC receiver operating characteristic.



**Supplementary Figure 5. The role of CDKN1A and CDKN2A in melanoma.** (**A**, **B**) The schematic diagrams show the location and downstream genes of CDKN1A and CDKN2A in the melanoma signaling pathway and cell cycle signaling pathway, respectively. The aberration frequency of each gene in melanoma patients was also marked. (**C**) The protein level of CDKN1A and CDKN2A in normal and melanoma tissues. The pictures of immunohistochemistry results with different magnifications. Brown represents the target protein. (**D**) The violin plots represent the expression of CDKN1A and CDKN2A in various subtypes, such as BRAF hotspot mutants, NF1 any mutants and triple WT.